EGFR and metastatic colorectal cancer: Two retrospective analyses demonstrated that patients with metastatic colorectal cancer (mCRC) exhibiting RAS mutations detected in ctDNA experienced markedly reduced response rates and shorter progression-free survival upon rechallenge with anti-EGFR therapies, compared to those without such mutations [58,59].